Sanofi turns down option to develop lumasiran

13 March 2018

US RNAi therapeutics company Alnylam Pharmaceuticals (Nasdaq: ALNY) says that Sanofi Genzyme, the biotech unit of French pharma major Sanofi (Euronext: SAN) has declined its opt-in for the development and commercialization of lumasiran (ALN-GO1), an investigational RNAi therapeutic for the treatment of primary hyperoxaluria Type 1 (PH1).

Based on this decision, Alnylam intends to rapidly advance lumasiran into a Phase III pivotal study in late 2018, and to commercialize lumasiran globally, assuming product approval. In addition, the company also announced that lumasiran has been granted Breakthrough Therapy designation (BTD) by the US Food and Drug Administration, representing the third BTD the company has received to date for programs in its pipeline.

The news did not disturb investors, as Alnylam’s shares moved higher, rising 5.4% to $149.59 by mid-morning.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK